Technetium (99mTc) sulesomab

Technetium (^99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody^[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of ^99mTc-antibody bound cells.^[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation^[3]

Technetium (^99mTc) sulesomab

Monoclonal antibody
Type	Fab' fragment
Source	Mouse
Target	NCA-90 (granulocyte cell antigen)
Clinical data
ATC code	V09HA04 (WHO)
Legal status
Legal status	AU: Approved
Identifiers
CAS Number	167747-19-5 Y
ChemSpider	none
UNII	709B6VM65P
NY (what is this?)  (verify)

It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis^[4][5] but has not secured FDA approval for use in American markets.^[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.^[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.^[10]